These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 35007366)

  • 1. Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer's disease.
    Terada T; Therriault J; Kang MS; Savard M; Pascoal TA; Lussier F; Tissot C; Wang YT; Benedet A; Poltronetti NM; Ottoy J; Arias JF; Bezgin G; Matsudaira T; Bunai T; Obi T; Tsukada H; Ouchi Y; Rosa-Neto P
    Eur J Neurol; 2022 May; 29(5):1324-1334. PubMed ID: 35007366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer's disease.
    Terada T; Therriault J; Kang MSP; Savard M; Pascoal TA; Lussier F; Tissot C; Wang YT; Benedet A; Matsudaira T; Bunai T; Obi T; Tsukada H; Ouchi Y; Rosa-Neto P
    Mol Neurodegener; 2021 Apr; 16(1):28. PubMed ID: 33902654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo mitochondrial and glycolytic impairments in patients with Alzheimer disease.
    Terada T; Obi T; Bunai T; Matsudaira T; Yoshikawa E; Ando I; Futatsubashi M; Tsukada H; Ouchi Y
    Neurology; 2020 Apr; 94(15):e1592-e1604. PubMed ID: 32139504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do Tau Deposition and Glucose Metabolism Dissociate in Alzheimer's Disease Trajectory?
    Nowell J; Raza S; Livingston NR; Sivanathan S; Gentleman S; Edison P
    J Alzheimers Dis; 2024; 101(3):987-999. PubMed ID: 39302365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
    Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R;
    Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tracer-specific reference tissues selection improves detection of
    Li Y; Ng YL; Paranjpe MD; Ge Q; Gu F; Li P; Yan S; Lu J; Wang X; Zhou Y;
    Hum Brain Mapp; 2022 May; 43(7):2121-2133. PubMed ID: 35165964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population.
    Frings L; Hellwig S; Bormann T; Spehl TS; Buchert R; Meyer PT
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1442-1448. PubMed ID: 29546632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparability of [
    Rodriguez-Vieitez E; Leuzy A; Chiotis K; Saint-Aubert L; Wall A; Nordberg A
    J Cereb Blood Flow Metab; 2017 Feb; 37(2):740-749. PubMed ID: 27107028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimer's disease, whereas amyloid deposition does not.
    Sang S; Pan X; Chen Z; Zeng F; Pan S; Liu H; Jin L; Fei G; Wang C; Ren S; Jiao F; Bao W; Zhou W; Guan Y; Zhang Y; Shi H; Wang Y; Yu X; Wang Y; Zhong C
    Alzheimers Res Ther; 2018 Mar; 10(1):26. PubMed ID: 29490669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo alterations of mitochondrial activity and amyloidosis in early-stage senescence-accelerated mice: a positron emission tomography study.
    Yamagishi S; Iga Y; Ikegaya S; Kakiuchi T; Ohba H; Nishiyama S; Fukomoto D; Kanazawa M; Harada N; Tsukada H; Sato K; Ouchi Y
    J Neuroinflammation; 2021 Dec; 18(1):288. PubMed ID: 34893067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.
    Chiotis K; Saint-Aubert L; Rodriguez-Vieitez E; Leuzy A; Almkvist O; Savitcheva I; Jonasson M; Lubberink M; Wall A; Antoni G; Nordberg A
    Mol Psychiatry; 2018 Jul; 23(7):1666-1673. PubMed ID: 28507319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
    Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease.
    Bunai T; Kakimoto A; Yoshikawa E; Terada T; Ouchi Y
    J Alzheimers Dis; 2019; 69(2):529-538. PubMed ID: 31104023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Benton Visual Retention Test Scores and PET Imaging in Elderly Adults.
    Abe M; Kimura N; Sasaki Y; Eguchi A; Matsubara E
    Curr Alzheimer Res; 2021; 18(11):900-907. PubMed ID: 34875990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.